Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Thomas Reinke
Enhancing Commercial Litigation: The Crucial Role of Forensic Accountants in Pre-Complaint Consultations
Click to enter your existing username and password or create a new account. Click to purchase an individual user subscription with your credit card. Expert OpinionCommercial Litigation The most powerful approach is to identify specific financial transactions, including supporting the claim with data and documents that provide evidence of damages.
Avoiding Errors in Discovery of Electronic Data
The discovery of information in commercial litigation and forensics is being transformed. Banker’s boxes with manila folders and photocopies have given way to secure uploads of digital files from new sources such as email, text, chat apps, video, and audio files. In foregone days, the goal was sorting through paper files to glean evidence. That manual workload has been replaced by powerful analytic software that races through electronic files.
Handy Township 2024 Primary Election results
Decision 2024 (WDIV) Here’s where you’ll find the 2024 Michigan Primary Election results for Handy Township. Click here to full Michigan primary election coverage. Bradley C. Redinger (R) 00% Michigan Primary Election Results 2024 Copyright 2024 by WDIV ClickOnDetroit - All rights reserved.
Data Tools in Litigation Support Miss Crucial Details
With this subscription you will receive unlimited access to high quality, online, on-demand premium content from well-respected faculty in the legal industry. This is perfect for attorneys licensed in multiple jurisdictions or for attorneys that have fulfilled their CLE requirement but need to access resourceful information for their practice areas. View Now Our Team Account subscription service is for legal teams of four or more attorneys.
Creating Powerful Litigation Complaints | Marcum LLP
The first formal step in litigation is drafting a persuasive and well-pleaded complaint. Poorly crafted complaints have a significant negative impact on litigation. They usually result in unnecessary and time-consuming amendments. If they omit a cause of action or factual allegations, they may result in limited discovery or omit significant damages. Marcum’s litigation support professionals are seeing important, broad-based changes in the state of the art for complaints.
Medical Billing: Maximizing the Power of Claims Scrubbers | Marcum LLP
Revenue cycle management is an ever-changing headache for medical practices. The challenges associated with it fall into five broad categories: Capturing and submitting complete information on services provided to patients. Ensuring a state-of-the-art billing system with features that maximize revenue. Effective and efficient billing policies and procedures. Managing staff. Keeping pace with payers and their reimbursement requirements. Each category brings unique challenges.
Health Care and Standards of Value in Contracts and Litigation
In the heavily regulated health care industry, attorneys are generally aware of the importance of fair market value (FMV). Our prior article addressed the impact of the anti-kickback statute (AKS) and the Stark Law (Stark) on the definition and elements of FMV. However, there are other standards of value (and valuation approaches) that are relevant for many business transactions, situations, and disputes in the health care industry, but are not governed by the AKS and Stark.
Prime Sees Dip in Opioids, Triptans as CGRP Inhibitor Scripts Take Off
Early real-world data about the first drugs specifically designed to prevent migraines shows they have had an impact on reducing the use of opioids and triptans to combat acute migraine attacks. That’s good news in a situation where the treatment of migraines is characterized by a patchwork of medicines. The opioids and triptans used to combat acute migraine attacks can be dangerous and inconsistently effective.
Evidence Mounts for IL-23 and IL-17 Inhibitors As Treatment for Psoriasis
A paradigm shift is underway in the treatment of psoriasis. Two newer classes of biologics, the interleukin 23 (IL-23) and interleukin 17 (IL-17) inhibitors are challenging the longstanding supremacy of tumor necrosis factor (TNF) inhibitors like Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab).
SGLT2 Inhibitors, No Diabetes Required?
The newest class of diabetes medicines, the sodium–glucose cotransporter 2 (SGLT2) inhibitors, are transforming medication therapy for diabetes patients with cardiovascular disease. Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin), the class leaders, first appeared on the market in 2013 and 2014 with indications for reducing HbA1c levels in people with type 2 diabetes. Since then, they have been on a steady course to expand into other populations and diseases.
To Be Continued: The Search for a Cure for HIV
It has been a disaster for humanity around the world, but there’s no denying that the human immunodeficiency virus is an absolutely brilliant microorganism when it comes to its own survival. As a virus, it normally would be fended off by the immune system. Somehow, though, HIV prevails over the immune system from the outset by infecting the very cells that are meant to trigger the immune system’s defense. The affected cells are CD4 T cells, a category of white blood cells.
Show Us (the U.S.) the Savings
In Europe, biosimilars are doing exactly what they are supposed to do: save money. In November the United Kingdom’s National Health Service announced a deal with AbbVie and four biosimilar manufacturers that will cut $378 million (£300 million) from its $504 million (£400 million) annual expenditure for Humira (adalimumab). That’s a savings of about 75%. The NHS said the savings was double its original estimates.
Rumble Over Drug Rebates As Pharma, Payers Duke It Out
Rebates remain front and center in the ongoing ruckus over high drug prices. Critics claim they are a primary driver of high drug prices because drug companies raise prices in response to payers’ demands for rebates in exchange for preferred placement on their formularies. They also vilify rebates as secretive backroom deals that line the pockets of PBMs, health plans, pharmacies, and drug distributors at the expense of consumers. PBMs and payers object.
Dupixent: Another Contender Prepares To Enter the Asthma Arena
Another new monoclonal antibody is on the horizon for the treatment of severe asthma. Sanofi and Regeneron’s Dupixent (dupilumab)—which is already approved for atopic dermatitis—has an FDA action date of October 20 for its asthma indication. About 8% of the general population and 12% of children have asthma. For most people with asthma, the condition can be well controlled with corticosteroids and beta-agonists. But between 5% and 10% have severe cases that resist all control.
In Cardiac Imaging, Things Are Looking Up for CTA
The first cardiac imaging tool, the electrocardiogram, was invented in 1902. It took another 50 years before the next modality, the echocardiogram, came along in 1953. Today, though, cardiac imaging, like all forms of technology, is advancing at breakneck speed. The current advances are not so much brand-new modalities as previous ones that now produce almost unimaginably detailed, vivid images. They put on a show that rivals a major Fourth of July fireworks display.
Aimovig for Migraine Prevention: The New Kid May Have Trouble Fitting In
In May the FDA approved a novel medication, Aimovig (erenumab-aooe), codeveloped by Amgen and Novartis, for the prevention of migraines. It’s novel in the classic sense that its mechanism of action is different than other migraine medications. But perhaps more interestingly, it is the first drug recently developed specifically for migraine prevention. The only other one, Sansert, was used during the ’60s but is off the market.
Trying to Sidestep Off-Label Dance-Around
The privilege of a medical license has long meant that physicians could prescribe drugs in ways that they think are best for their patients, not necessarily just for their FDA-approved indications. Where a license is a privilege, free speech is a right. Drug companies have long claimed the FDA has been trampling on their free speech rights by keeping clamps on what they can tell doctors about using their drugs for indications beyond those the agency has approved.
How RWE Is Becoming the Real Deal
Second of two parts The FDA is laying groundwork that will play a major role in determining the future of real-world evidence. In just a few years the use of RWE has expanded dramatically, but it has yet to establish a clear role for itself. As evidence, it continues to take a back seat to randomized controlled trials, especially in the development of clinical guidelines. But the back seat doesn’t mean there isn’t a seat at the table for RWE.
CVS To Dominate Pharmacy Networks
It doesn’t get much more saturated than this: 99.9% of Medicare Part D beneficiaries are enrolled in prescription drug plans with preferred pharmacy networks, according to pharmacy markets expert Adam J. Fein of Pembroke Consulting.
Real-World Evidence Not Quite Believable Enough
First of two parts The idea of using real-world evidence to improve health care is really something of a no-brainer. It’s just plain common sense. Clinical guidelines to aid practitioners’ everyday decisions aren’t available for 85% of services, and there is a constant onslaught of new procedures and treatment options that need to be evaluated as they are used in clinical practice and not in the controlled and fundamentally artificial context of a clinical trial.
Hemlibra's Remarkable Efficacy A Beacon for Hemophilia Patients
Hemophilia has been recognized for thousands of years. A second century collection of Jewish rabbinical writings describing Jewish laws and traditions allowed for a waiver from circumcision if two brothers of a newborn had previously died after circumcision. This reference is thought to be the first description of what we now call hemophilia.
The Show-me State Shows the Way On ‘Health Homes’ for Mental Health
For private health insurers and payers of all types, people with both mental and physical health problems may be the most challenging. They are often among the “high utilizers”—the 5% of patients who account for about half of health care spending. Not only do they have high medical costs, but many of them also have a serious mental illness such as schizophrenia, bipolar disorder, or major depression.
Underused Weapon In the War on Addiction
Numbers tell part of the story of the nation’s opioid crisis. The CDC says 91 Americans die daily from opioid overdoses, which have killed more than 300,000 since 2000—and the death rate is rising. But to John Machata, MD, of Wickford, R.I., some of the numbers have faces. He remembers the call he got not long ago about a former patient he hadn’t seen in a year, a fisherman who had lost his insurance and couldn’t stick with his drug rehab program.
PBMs: Will the Amazon cometh?
A few months ago Linda Cahn was pondering how a retailing giant might change the current PBM business model of convoluted contract language, secret side deals, opaque pricing structures, and the like. “A Walmart, Costco, or Amazon could create a truly transparent PBM,” said Cahn, a PBM consultant and an ardent critic of the industry. “That would implode the current model.” Well, we may soon find out.
Opioids, Part 1 | Managed Care magazine
Do something!” seems to be the message to health insurers about the opioid epidemic from patients, physicians, and addiction experts. The numbers alone suggest a pressing need to take action. A staggering 33,000 Americans died of opioid-related deaths in 2015, the most recent year for which complete data are available. The number of deaths from opioids are likely to be even higher in 2016 than in 2015 once the final count for that year is in.
Disasters | Managed Care magazine
Disaster seems to be a new kind of normal, still unpredictable but no longer unexpected. It’s impossible to say what calamities 2018 will bring, but payers, providers, and regulators are going into the new year with an armamentarium of tools—and new requirements—for responding when large numbers of people suddenly have new health care needs. Telehealth is one of the tools.
Drug Prices | Managed Care magazine
Are controversy and the threat of government intervention chilling drug-price increases or heating them up? As the start of 2018 approaches, Stephen Schondelmeyer, PharmD, PhD, takes the latter view. Reports that Congress or the Executive Branch may do something about drug prices don’t slow increases, says Schondelmeyer, head of the Department of Pharmaceutical Care and Health Systems at the University of Minnesota College of Pharmacy and a member of Managed Care’s Editorial Advisory Board.
ACA Repeal | Managed Care magazine
A year ago you probably couldn’t find a Las Vegas bookmaker willing to give odds that the ACA would still be the law of the land in 2018. In gamblerspeak, it was off the board. With control of both houses of Congress and the presidency, the GOP could finally make good on their seven-year promise to repeal and replace President Barack Obama’s signature health care legislation. Turns out, repealing the ACA and crafting a replacement acceptable to the party’s disparate factions isn’t so easy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Thomas
Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack